C3 signs Italian distributor
Friday, 11 June, 2004
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX:CCE) has signed Rome-based Health Defence to distribute its CellSpray and ReCell products in Italy.
CellSpray, a suspension of cultured skin cells, is used to treat major burns and scars. ReCell, an autologous skin harvesting device, will be marketed primarily for plastic and cosmetic surgery.
CEO Troels Jordansen said that C3 currently had distribution agreements for its products in place in Ireland, the UK, Germany, Switzerland, Holland, Belgium Luxembourg and France.
In April C3 also signed distribution agreements with Equipmed to market CellSpray and ReCell in Australia, excluding Western Australia, and New Zealand
The company is currently negotiating with distributors in the USA, Japan, South Africa, India and Brazil. It expects to sell its products in approximately 20 countries worldwide. Jordansen said he was confident that agreements will be in place in time for the launch of ReCell in 2005.
Health Defence will begin distributing the product once they have gained European CE Mark approval, anticipated at the end of this year.
“ReCell will be the big distribution generator,” said CEO Troels Jordan. “We will be focusing on the global cosmetic markets.”
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...